Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $310.61M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.38M
Average 1.73M
LRMR Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Net Margin history
Percent of revenue · from the income statement
No Net Margin data reported for this period type.
Net Margin vs competitors
How LRMR compares with its peers on the latest reported figures
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -15.6% | +25.4 pp | +10.5 pp | |
| LTM Mar 2026 | -1788.8% | -1604.7 pp | -173.6 pp | |
| LTM Mar 2026 | -2954.1% | -1141.0 pp | — | |
| LTM Mar 2026 | -253002.8% | +198197.2 pp | -339438.9 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
LXEOLexeo Therapeutics, Inc. Common Stock | FY2025 | — | — | — |
ENGNenGene Holdings Inc. | FY2025 | — | — | — |
| Peer median (excluding LRMR) | -2371.5% | -557.8 pp | -173.6 pp | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.